Health Economics

A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: priority weights
Øystein Ariansen Haaland, Frode Lindemark, Kjell Arne Johansson

medRxiv 19003780; doi: https://doi.org/10.1101/19003780
Why so many significant Phase 3 results in clinical trials?
Jerome Adda, Christian Decker, Marco Ottaviani

medRxiv 19001495; doi: https://doi.org/10.1101/19001495